Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 5/20 | 0.73 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.51 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.51 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29243986 | 0.90 | PNP (0.59) | PNPMAPTKDM4EMEN1ALDH1A1 | |
| 8-Aminoguanine SCHEMBL21761 | 0.85 | PNP (1.00) | PNPMAPTKDM4EMEN1ALDH1A1 | |
| Niacinamide SCHEMBL6559649 | 0.76 | PNP (0.55) | PNPMAPTKDM4EMEN1ALDH1A1 | |
| SCHEMBL22883 | 0.76 | PNP (0.73) | PNPMAPTKDM4EMEN1ALDH1A1 | |
| SCHEMBL2051361 | 0.76 | PNP (0.73) | PNPMAPTKDM4EMEN1ALDH1A1 | |
| SCHEMBL843932 | 0.76 | PNP (0.73) | PNPMAPTKDM4EMEN1ALDH1A1 | |
| SCHEMBL844207 | 0.76 | PNP (0.73) | PNPMAPTKDM4EMEN1ALDH1A1 | |
| SCHEMBL42760 | 0.76 | PNP (0.73) | PNPMAPTKDM4EMEN1ALDH1A1 | |
| SCHEMBL20577 | 0.76 | PNP (0.73) | PNPMAPTKDM4EMEN1ALDH1A1 | |
| SCHEMBL6686388 | 0.76 | PNP (0.73) | PNPMAPTKDM4EMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2437 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026106497-A2 | FUNCTIONALIZED CIRCULAR RNA AND METHODS AND INTERMEDIATES FOR THEIR PRODUCTION | SIEĆ BADAWCZA ŁUKASIEWICZ – PORT POLSKI OSRODEK ROZWOJU TECHNOLOGII (PL) | 2026-05-21 | — | — | WO | claimed |
| EP-4638717-A2 | ENGINEERED RNA LIGASE VARIANTS | Codexis, Inc. (US) | 2025-10-29 | — | — | EP | claimed |
| US-20250295658-A1 | ANTIPARASITIC AGENTS AND METHODS | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH | 2025-09-25 | — | — | US | claimed |
| EP-4619524-A1 | METHODS AND COMPOSITIONS FOR PREVENTING, TREATING, OR REVERSING CARDIAC DIASTOLIC DYSFUNCTION | Genkardia Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| US-20250257360-A1 | OLIGONUCLEOTIDE INTERFERENCE TREATMENTS OF PROSTATE CANCER | UNIV OKLAHOMA (US) | 2025-08-14 | — | — | US | claimed |
| CN-113151261-B | Antisense oligonucleotides as inhibitors of TGF-R signaling | 神经视觉医药有限公司 | 2025-06-17 | — | — | CN | claimed |
| WO-2025111510-A1 | ENGINEERED RNA LIGASES | CODEXIS, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| EP-4504945-A2 | OLIGONUCLEOTIDE INTERFERENCE TREATMENTS OF PROSTATE CANCER | The Board of Regents of the University of Oklahoma (US) | 2025-02-12 | — | — | EP | claimed |
| CN-118931997-A | Method for synthesizing adenosine and/or uridine by three-enzyme cascade catalysis | 上海飞腾医药科技有限公司 | 2024-11-12 | — | — | CN | claimed |
| US-20240294924-A1 | ANTISENSE-OLIGONUCLEOTIDES FOR PREVENTION OF KIDNEY DYSFUNCTION PROMOTED BY ENDOTHELIAL DYSFUNCTION BY EPHRIN-B2 SUPPRESSION | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2024-09-05 | — | — | US | claimed |
| WO-1996016972-A1 | PURINE NUCLEOSIDE MODIFICATIONS BY PALLADIUM CATALYZED METHODS | NEXSTAR PHARMACEUTICALS, INC. (US) | 1996-06-06 | — | — | WO | claimed |
| US-5438130-A | Fucosylated guanosine disulfates as excitatory amino acid antagonists | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1995-08-01 | — | — | US | claimed |
| WO-1995008003-A1 | SYSTEMATIC EVOLUTION OF LIGANDS BY EXPONENTIAL ENRICHMENT: PHOTOSELECTION OF NUCLEIC ACID LIGANDS AND SOLUTION SELEX | UNIVERSITY RESEARCH CORPORATION (US) | 1995-03-23 | — | — | WO | claimed |
| US-5386030-A | Chemical intermediates | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCE OF THE CZECH REPUBLIC (CZ) | 1995-01-31 | — | — | US | claimed |
| EP-0630381-A4 | ANTIVIRAL ACYCLIC PHOSPHONOMETHOXYALKYL SUBSTITUTED, ALKENYL AND ALKYNYL PURINE AND PYRIMIDINE DERIVATIVES. | — | 1995-01-04 | — | — | EP | claimed |
| EP-0630381-A1 | ANTIVIRAL ACYCLIC PHOSPHONOMETHOXYALKYL SUBSTITUTED, ALKENYL AND ALKYNYL PURINE AND PYRIMIDINE DERIVATIVES. | ACAD OF SCIENCE CZECH REPUBLIC (CS) | 1994-12-28 | — | — | EP | claimed |
| WO-1994015622-A1 | NUCLEOSIDE DERIVATIVES AND THEIR USE AS EXCITATORY AMINO ACID ANTAGONISTS | CAMBRIDGE NEUROSCIENCE (US) | 1994-07-21 | — | — | WO | claimed |
| US-5208221-A | Nucleotides and intermediates for herpes virus or leukemia virus | BRISTOL-MYERS SQUIBB COMPANY (US) | 1993-05-04 | — | — | US | claimed |
| WO-1993007157-A1 | ANTIVIRAL ACYCLIC PHOSPHONOMETHOXYALKYL SUBSTITUTED, ALKENYL AND ALKYNYL PURINE AND PYRIMIDINE DERIVATIVES | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OFTHE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 1993-04-15 | — | — | WO | claimed |
| EP-0269947-A1 | Antiviral phosphonomethoxyalkylene purine and pyrimidine derivatives | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CS) | 1988-06-08 | — | — | EP | claimed |